Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
210 hedge funds and large institutions have $2.03B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 76 increasing their positions, 75 reducing their positions, and 43 closing their positions.
70% more call options, than puts
Call options by funds: $94.8M | Put options by funds: $55.8M
1% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 75
10% less capital invested
Capital invested by funds: $2.26B → $2.03B (-$232M)
10% less funds holding
Funds holding: 234 → 210 (-24)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
35% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$214M |
| 2 |
DM
Deerfield Management
New York
|
+$32.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$28.9M |
| 4 |
SCM
Scopia Capital Management
New York
|
+$26M |
| 5 |
Barclays
London,
United Kingdom
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$60.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$52.6M |
| 3 |
CGM
Capital Growth Management
Boston,
Massachusetts
|
-$24.8M |
| 4 |
LPC
Lion Point Capital
New York
|
-$18.8M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$18M |
HZNP Hedge Fund Activity: Q1 2017 in Review
210 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2017, worth a combined $2.03B — down 10% from $2.26B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of HZNP and 28 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 76 added.
The largest buyer was BlackRock, adding an estimated $214M. The largest seller was Kingdon Capital Management, cutting an estimated $60.3M.
- 210 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2017, down from 234 in Q4 2016.
- Funds reported $2.03B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2017, down 10% quarter-over-quarter.
- 28 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2017 and 43 closed out, a net change of -15 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2017 was BlackRock, an estimated $214M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2017 was Kingdon Capital Management, an estimated $60.3M sold.
Based on aggregated 13F filings for Q1 2017.